The table below shows DiaMedica Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$9.08M
-$7.15M
-$6.65M
-$5.09M
-$3.89M
-$4.31M
Capital expenditure
$8.00K
$12.00K
$9.00K
$7.00K
$0.00
$9.00K
Investing cash flow
-$2.11M
$6.62M
$4.21M
$2.51M
$2.21M
-$9.00K
Dividends paid
-
-
-
-
DMAC operating cash flow (10-K history)
DiaMedica Therapeutics Inc. reported operating cash flow of -$29.06M for fiscal year 2025. That is down 31.6% from -$22.08M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$3.90M (FY 2017) to -$29.06M. Figures come from the company's audited annual reports as filed with the SEC.